申请人:Godecke Aktiengesellschaft
公开号:US04698341A1
公开(公告)日:1987-10-06
New 1,6-naphthyridinone derivatives of the formula I ##STR1## are herein described wherein R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic ring; R.sup.2 is hydrogen, a straight-chained or branched alkyl, alkoxyalkyl, or a substituted or unsubstituted aminoalkyl group with up to ten carbon atoms; R.sup.3 is hydrogen, a straight-chained or branched alkyl group, or an alkoxycarbonyl radical with up to four carbon atoms; R.sup.4 is hydrogen, or a morpholinoethyl group; R.sup.5 is a straight-chained or branched alkyl group with up to four carbon atoms, or an amino group; and R.sup.6 is a carboxyl group, or an alkyl- or alkyloxyalkyl carbonyl radical, containing up to 12 carbon atoms and optionally interrupted by an oxygen, sulphur, or nitrogen atom; as well as optionally the pharmacologically acceptable salts thereof; processes for the preparation of these derivatives and their use in the control of vascular diseases.
本文介绍了式I的新型1,6-萘啶酮衍生物,其中R.sup.1代表未取代或取代的芳香或杂芳环;R.sup.2为氢,直链或支链烷基,烷氧基烷基,或取代或未取代的氨基烷基,其碳原子数不超过十个;R.sup.3为氢,直链或支链烷基,或具有最多四个碳原子的烷氧羰基基团;R.sup.4为氢或吗啉基乙基基团;R.sup.5为具有最多四个碳原子的直链或支链烷基或氨基;R.sup.6为羧基或含有最多12个碳原子的烷基或烷氧基烷基羰基基团,可选地被氧、硫或氮原子中断;以及它们的药学上可接受的盐;制备这些衍生物的方法以及它们在控制血管疾病中的应用。